spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

14th World Advanced Therapies & Regenerative Medicine Congress 2018

World_Advanced_Therapies_and_Regenerative_Medicine_Congress_2019

16-18 May 2018
Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From clinical translation to commercialisation this congress will bring you the most exciting case studies and new data for stem cells, gene therapy, TCRs and gene editing. Experts in every area will help you tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic.

The event will take place alongside the co-located World Precision Medicine Congress, hosting300+ speakers, 10 tracks of content across the 3 days, enabling networking opportunities with 800+ leading industry professionals.

For a 15% discount on your conference ticket, quote code ‘HMFQ’ at the online checkout

Confirmed speakers include:

•                   Susan Solomon, CEO and Co-Founder, New York Stem Cell Foundation

•                   Sven Kili, Vice President & Head, Gene Therapy Development, GSK

•                   Eric Soller, Vice President of Corporate Development & Strategy, BlueRock Therapeutics

•                   Margo Roberts, CSO, Kite Pharma

•                   Sue Hill, Chief Scientific Officer, NHS

•                   Brad Perkins, Chief Medical Officer, Human Longevity

•                   Julia Wilson, Associate Director, Wellcome Trust Sanger Institute

•                   Paul P. Tak, Academic Medical Centre, University of Amsterdam;  Senior Vice President of Research & Development Pipeline, Chief Immunology Officer, GSK

•                   Elizabeth Shpall, Director, MD Anderson Cancer Center

•                   Joanne Kurtzberg, Director, Carolinas Cord Blood Bank, Duke University

•                   Todd McAllister, Executive Director, Amnion Foundation

•                   Colleen Delaney, Founder and Chief Medical Officer, Nohla Therapeutics

•                   Ajan Reginald, Chief Executive Officer, Celixir

•                   Alain Vertθs, Managing Director, NxR Biotechnologies

•                   Andrι Choulika, Chairman & Chief Executive Officer, Cellectis

•                   Benjamin Shepherd, Director, Therapeutics, Organovo

•                   Eduardo Bravo, Managing Director and CEO, TiGenix

•                   Giuseppe Mazza, Chief Executive & Scientific Officer, Engitix

•                   James Miskin, Chief Technical Officer, Oxford BioMedica

•                   Jane Lebkowski, ‎President of R&D, Asterias Biotherapeutics

•                   Jeff Abbey, CEO, Argos Therapeutics

•                   John Tchelingerian, CEO, Promethera, Biosciences

•                   Katy Spink, Chief Operating Officer, Asterias Biotherapeutics

•                   Kristin Comella, Chief Science Officer, US Stem Cell Inc

•                   Michael Stein, Chairman & CEO, Oxstem

•                   Michael West, CEO, BioTime; CEO , AgeX Therapeutics

•                   Nick Crabb, Programme Director – Scientific Affairs, NICE

•                   Todd McAllister, Executive Director, Amnion Foundation

•                   Yen Choo, CEO, Progenitor Therapeutics

•                   Zami Aberman, Chairman & CEO, Pluristem Therapeutics

Key topics include:

•                   The next generation of ATMPs

•                   Regulation, reimbursement & commercialisation for advanced therapies around the globe

•                   CRISPR & gene editing

•                   Stem cells as a tool for drug discovery

•                   What’s next for cell and gene therapy, new era of regenerative medicine?

•                   New paradigms in manufacture: gene therapy & viral vectors

•                   Clinical development of immunotherapy & cell therapy

•                   New frontiers in repair and replacement of diseased tissues & organs

•                   Product, process & manufacturing development of ATMPS

For a 15% discount on your conference ticket, quote code ‘HMFQ’ at the online checkout

phone +44 (0)20 7092 1000
email enquiry.uk@terrapinn.com
web bit.ly/2AUXmW3
email Business Design Centre, London
 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>


News and Press Releases

Optimizing pharmaceutical processes

An increase in requirements from regulatory agencies around the world, combined with a growing demand for drugs in prefilled injections systems – a trend that industry experts have projected will continue – has led pharmaceutical and biotech supply chains to gain in significance. Well established and optimized processes are crucial for offering uninterrupted market supply. To satisfy its customers a CDMO must foster flexibility, efficiency and safety throughout the entire supply chain. The most important goal for all parties involved in the bio-pharma business is maximization of product quality where even small decisions can make a big difference. Future-oriented pharma processes can add value to any compound.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement